Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Alliance for Clinical Trials in Oncology
Study ID
NCT00004139
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of gemcitabine plus either docetaxel or irinotecan in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Key Dates

Start date
Sep 30, 1999
Status verified
Jul 2016
Primary completion
Jul 31, 2004
Completion
Jan 31, 2006

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Gemcitabine + Irinotecan
  • Experimental: Gemcitabine + Docetaxel

Primary Outcome Measure

response rate [ Time Frame: Up to 2 years ]

Locations (8)

FacilityCityStateZIPSite coordinators
Vincent T. Lombardi Cancer Research Center, Georgetown UniversityWashington D.C.District of Columbia20007-
Walter Reed Army Medical CenterWashington D.C.District of Columbia20307-5000-
Barnes-Jewish HospitalSt LouisMissouri63110-
CCOP - Southern Nevada Cancer Research FoundationLas VegasNevada89106-
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-
Medical University of South CarolinaCharlestonSouth Carolina29425-0721-
CCOP - GreenvilleGreenvilleSouth Carolina29615-
University of Tennessee, Memphis Cancer CenterMemphisTennessee38163-

Find similar trials in Washington D.C., DC

By condition

Related Studies